Novo Nordisk stock trades at DKK 253.00 as Citi keeps target at DKK 310.00
Published on 09/28/2026 at 15:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk (ISIN DK0060534915) closed at DKK 253.00 on Nasdaq Copenhagen on September 25, 2026, unchanged on the session. According to MarketScreener, Citi keeps a Neutral rating and a DKK 310.00 price target following the companys September 21, 2026 Capital Markets Day.
Targets remain above the price
Investing.com lists a DKK 307.60 average 12-month target from 23 analysts, alongside a Neutral consensus of 5 Buy, 16 Hold and 4 Sell ratings. The average target stands DKK 54.60 above the September 25 price, while Citi's DKK 310.00 target is DKK 57.00 higher.
The spread between the market price and the targets makes valuation expectations the central issue for Novo Nordisk stock. Citi said the Capital Markets Day offered little reason to change its cautious view, while Wegovy Pill and CagriSema could counter pricing pressure if execution remains effective.
Q2 results set the operating base
According to Novo Nordisk, the company announced its Q2 2026 financial results on August 4, 2026, with an earnings call on August 5. The companys portfolio centers on diabetes and obesity care, alongside rare-disease treatments.
The next scheduled reporting date is November 4, 2026, when Novo Nordisk plans to announce results for the first three quarters of 2026. That date gives investors a defined checkpoint for judging demand, pricing and execution against the targets now clustered above DKK 300.00.
Stock stays well below its yearly high
The DKK 253.00 closing price was 12.80 percent above the 52-week low of DKK 224.30 and 38.29 percent below the 52-week high of DKK 410.00, based on the September 25, 2026 snapshot. Novo Nordisk B shares are listed on Nasdaq Copenhagen under Novo-B, while the companys ADRs trade separately on the New York Stock Exchange under NVO, as Via Ritzau reports.
Novo Nordisk stock snapshot
- Company: Novo Nordisk A/S
- ISIN: DK0060534915
- Ticker: Novo-B
- Trading venue: Nasdaq Copenhagen
- Price (as of September 25, 2026): Closing price DKK 253.00
- 52-week range: DKK 224.30-410.00
- Sector / Industry: Healthcare / Pharmaceuticals
- Next earnings date: November 4, 2026
